Xaira Therapeutics
AI drug discovery company launched in 2024 with $1B in committed funding, fusing ML and wet-lab biology
Biotech
📍 South San Francisco, CA
Founded 2023
Current Valuation
$1.0B
as of 2024-Q2
UNICORN
Xaira Therapeutics launched in April 2024 with $1 billion in committed funding — among the largest biotech Series A rounds ever — incubated by ARCH Venture Partners and Foresite Labs. CEO Marc Tessier-Lavigne is the former president of Stanford University and former CSO of Genentech. The platform builds on RFdiffusion and protein-design discoveries from David Baker's lab at the University of Washington (where Baker won the 2024 Nobel Prize in Chemistry). Targeting oncology and immunology indications.
Company Profile
HQ
South San Francisco, CA
Growth
Pre-revenue / pre-clinical
Last Round
Series A — $1.0B (Apr 2024) · Lead: ARCH Venture Partners + Foresite Labs (co-leads)
IPO Status
no imminent plans
Founders & Key People
Marc Tessier-LavigneRobert PlengeJohn Maraganore
Investors
ARCH Venture Partners · Foresite Labs · F-Prime Capital · NEA · Sequoia · Lightspeed · Two Sigma Ventures · Ravelin Capital
Products
- AI-discovered therapeutic pipeline (oncology, immunology)
- Computational platform from RFdiffusion + Baker Lab discoveries
Competitors
Isomorphic Labs · Insitro · Recursion · Atomic AI · Generate Biomedicines
BiotechAI Drug DiscoveryMega-Round
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2024-Q2. Refreshed quarterly.